Ascendis Pharma A/S (NASDAQ:ASND) Stock Rating Upgraded by Wedbush

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by equities researchers at Wedbush to a “strong-buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports.

Other research analysts also recently issued research reports about the company. Cantor Fitzgerald restated an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a report on Monday. Evercore ISI upped their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a report on Tuesday, September 17th. Bank of America raised their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. TD Cowen upped their price target on Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Finally, The Goldman Sachs Group upped their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $195.92.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ:ASND opened at $128.13 on Monday. The firm has a fifty day moving average of $133.17 and a 200 day moving average of $133.46. Ascendis Pharma A/S has a 52-week low of $86.54 and a 52-week high of $161.00. The firm has a market capitalization of $7.77 billion, a PE ratio of -13.76 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. On average, sell-side analysts forecast that Ascendis Pharma A/S will post -7.24 EPS for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Institutional investors have recently made changes to their positions in the business. Signaturefd LLC raised its position in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 80 shares during the period. Bessemer Group Inc. raised its stake in shares of Ascendis Pharma A/S by 61.0% in the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after buying an additional 332 shares during the period. Searle & CO. purchased a new position in shares of Ascendis Pharma A/S during the 2nd quarter valued at about $205,000. Rhumbline Advisers grew its stake in shares of Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 143 shares during the period. Finally, Pursue Wealth Partners LLC purchased a new stake in Ascendis Pharma A/S in the 3rd quarter worth approximately $217,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.